As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new jobs at its manufacturing site at the Philadelphia Navy Yard ...

Iovance has its gene therapy manufacturing plant at the Philadelphia Navy Yard. Iovance officially opens $125M cell therapy center at the Navy Yard © 2025 American ...

AMTAGVI will be manufactured in Philadelphia at the Iovance Cell Therapy Center (iCTC), with capacity for up to several thousand patients annually, including a nearby contract manufacturer.

Iovance, which specializes in developing treatments ... The proceeds will help fund the company's Philadelphia manufacturing facility, as well as preparations for the commercial launch of its ...

Iovance Biotherapeutics (NASDAQ: IOVA) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable ...

They recall a time when Philadelphia’s Navy Yard hummed with ... is currently home to commercial tenants, including Iovance Biotherapeutics, but residents will arrive this fall.

Iovance Biotherapeutics shares fell 6.41% after appointing Dan Kirby as Chief Commercial Officer, signaling investor concerns. The decline reflects skepticism about the company's growth trajectory ...

Iovance Biotherapeutics shares were 42% lower, at $1.84, after the company said its first-quarter loss was wider than analysts' expectations. The biotechnology company said it had a quarterly loss ...

These are exciting times to be an Iovance Biotherapeutics (NASDAQ: IOVA) shareholder. The biotech has made encouraging clinical and regulatory progress in the past year. Its most important product ...